亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

LI-RADS CT and MRI Ancillary Feature Association with Hepatocellular Carcinoma and Malignancy: An Individual Participant Data Meta-Analysis

医学 肝细胞癌 恶性肿瘤 荟萃分析 优势比 逻辑回归 放射科 置信区间 内科学
作者
Haben Dawit,Eric Lam,Matthew D. F. McInnes,Christian B. van der Pol,Mustafa R. Bashir,Jean‐Paul Salameh,Brooke Levis,Claude B. Sirlin,Victoria Chernyak,Sang Hyun Choi,So Yeon Kim,Tyler J. Fraum,An Tang,Hanyu Jiang,Bin Song,Jin Wang,Stephanie R. Wilson,Heejin Kwon,Andrea S. Kierans,Ijin Joo
出处
期刊:Radiology [Radiological Society of North America]
卷期号:310 (2) 被引量:7
标识
DOI:10.1148/radiol.231501
摘要

Background The independent contribution of each Liver Imaging Reporting and Data System (LI-RADS) CT or MRI ancillary feature (AF) has not been established. Purpose To evaluate the association of LI-RADS AFs with hepatocellular carcinoma (HCC) and malignancy while adjusting for LI-RADS major features through an individual participant data (IPD) meta-analysis. Materials and Methods Medline, Embase, Cochrane Central Register of Controlled Trials, and Scopus were searched from January 2014 to January 2022 for studies evaluating the diagnostic accuracy of CT and MRI for HCC using LI-RADS version 2014, 2017, or 2018. Using a one-step approach, IPD across studies were pooled. Adjusted odds ratios (ORs) and 95% CIs were derived from multivariable logistic regression models of each AF combined with major features except threshold growth (excluded because of infrequent reporting). Liver observation clustering was addressed at the study and participant levels through random intercepts. Risk of bias was assessed using a composite reference standard and Quality Assessment of Diagnostic Accuracy Studies 2. Results Twenty studies comprising 3091 observations (2456 adult participants; mean age, 59 years ± 11 [SD]; 1849 [75.3%] men) were included. In total, 89% (eight of nine) of AFs favoring malignancy were associated with malignancy and/or HCC, 80% (four of five) of AFs favoring HCC were associated with HCC, and 57% (four of seven) of AFs favoring benignity were negatively associated with HCC and/or malignancy. Nonenhancing capsule (OR = 3.50 [95% CI: 1.53, 8.01]) had the strongest association with HCC. Diffusion restriction (OR = 14.45 [95% CI: 9.82, 21.27]) and mild-moderate T2 hyperintensity (OR = 10.18 [95% CI: 7.17, 14.44]) had the strongest association with malignancy. The strongest negative associations with HCC were parallels blood pool enhancement (OR = 0.07 [95% CI: 0.01, 0.49]) and marked T2 hyperintensity (OR = 0.18 [95% CI: 0.07, 0.45]). Seventeen studies (85%) had a high risk of bias. Conclusion Most LI-RADS AFs were independently associated with HCC, malignancy, or benignity as intended when adjusting for major features. © RSNA, 2024

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
顾矜应助爱笑的傲晴采纳,获得10
8秒前
17秒前
20秒前
22秒前
26秒前
31秒前
47秒前
科研通AI6应助lemon采纳,获得30
51秒前
1分钟前
1分钟前
KINGAZX完成签到 ,获得积分10
1分钟前
hahha发布了新的文献求助10
1分钟前
1分钟前
圆圆901234发布了新的文献求助10
1分钟前
英俊的铭应助hahha采纳,获得10
1分钟前
1分钟前
LHL完成签到,获得积分10
1分钟前
LeslieHu发布了新的文献求助10
1分钟前
1分钟前
圆圆901234完成签到,获得积分10
1分钟前
null应助科研通管家采纳,获得10
1分钟前
null应助科研通管家采纳,获得10
1分钟前
null应助科研通管家采纳,获得10
1分钟前
null应助科研通管家采纳,获得10
1分钟前
科研通AI6应助科研通管家采纳,获得30
1分钟前
null应助科研通管家采纳,获得10
1分钟前
null应助科研通管家采纳,获得10
1分钟前
1分钟前
1分钟前
笨笨的怜雪完成签到 ,获得积分10
1分钟前
mumu发布了新的文献求助10
1分钟前
2分钟前
万能图书馆应助mumu采纳,获得10
2分钟前
2分钟前
2分钟前
2分钟前
inRe发布了新的文献求助10
2分钟前
3分钟前
3分钟前
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Encyclopedia of Reproduction Third Edition 3000
《药学类医疗服务价格项目立项指南(征求意见稿)》 1000
花の香りの秘密―遺伝子情報から機能性まで 800
1st Edition Sports Rehabilitation and Training Multidisciplinary Perspectives By Richard Moss, Adam Gledhill 600
Chemistry and Biochemistry: Research Progress Vol. 7 430
Bone Marrow Immunohistochemistry 400
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5628241
求助须知:如何正确求助?哪些是违规求助? 4716158
关于积分的说明 14963847
捐赠科研通 4785915
什么是DOI,文献DOI怎么找? 2555467
邀请新用户注册赠送积分活动 1516748
关于科研通互助平台的介绍 1477316